Contamination Source Identification Revenue and Competitors
Estimated Revenue & Valuation
- Contamination Source Identification's estimated annual revenue is currently $1.4M per year.
- Contamination Source Identification's estimated revenue per employee is $155,000
Employee Data
- Contamination Source Identification has 9 Employees.
- Contamination Source Identification grew their employee count by -47% last year.
Contamination Source Identification's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Computational Informatics | Reveal Email/Phone |
Contamination Source Identification Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Contamination Source Identification?
At Contamination Source Identification (CSI®) we are revolutionizing the standard of diagnostics. Our CLIA-certified laboratory is fully automated with proprietary laboratory processes that improve speed and reduce contamination. Our highly-talented and experienced team is comprised of professionals with varying backgrounds including computational experts, molecular biologists, bioinformaticists, researchers, lab technicians, and a medical officer. We have proudly provided the first and only RNA sequencing test for Tickborne disease state. We continue to contribute meaningfully to the delivery of patient care by providing physicians with accurate active pathogen identification to enable confident disease diagnosis and targeted treatment decisions that encompass all infective pathogens and any contributing factors. Using our proprietary CSI-DX™ test, we are able to identify and report on all active infections and co-infections found in a sample. With faster identification turn-around times and state-of-the-art equipment, we improve physicians’ ability to deliver accurate treatment earlier, preventing the disease from developing additional symptoms and long-term effects, helping to prevent the disease from developing additional symptoms and long-term effects.
keywords:N/AN/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-47%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.6M | 10 | 11% | N/A |
#2 | $1.3M | 10 | -33% | N/A |
#3 | $3M | 14 | -7% | N/A |
#4 | $1.8M | 17 | 31% | N/A |
#5 | $15M | 21 | 24% | N/A |